Systemic sclerosis & Raynaud's
Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis
Authors' conclusion
Selexipag showed good potential for the treatment of SSc digital vasculopathy.
Study context
- Population
- Patients with systemic sclerosis (SSc) with severe digital vasculopathy refractory or with contraindication to all other vasoactive therapies (66.6% female, mean age 52.3 [SD 16.6] yrs)1 stopped for adverse effects
- Participants
- 9 patients
- Exposure
- Selexipag, baseline vs after 3 months
- Selexipagn = 9
- Outcome
- RP- and DU-related clinical outcomes and digital perfusion by laser speckle contrast analysis (LASCA)
- Follow-up
- 3 months
Methodological detailssingle-group, before-after (baseline vs 3 months)
- Single-group
- Before-after (baseline vs 3 months)
Main finding
As reported in the abstract
RP- and DU-related outcomes and digital perfusion, baseline vs 3 months
- Significant reduction in Raynaud phenomenon (RP) daily episodes
- P = 0.01
- Significant reduction in RP mean duration
- P = 0.04
- Significant improvement in mean perfusion of the fingers (laser speckle contrast analysis (LASCA))
- P = 0.02
Observational data: associations, not effects.
Safety
Discontinuation because of adverse effects
- One patient had to stop the drug because of adverse effects
- 1
Original publication
Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis. J Rheumatol. Published 1 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →